Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Lung Cancer Metastatic × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Stomach Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasm Metastasis 1 Muscle Invasive Bladder Cancer 1 Meningioma 1 Lung Neoplasms 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 DLBCL 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

pembrolizumab 3 Bevacizumab 3 tusamitamab ravtansine 2 Ramucirumab 2 Pemetrexed 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Docetaxel 2 Carboplatin 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 vistusertib 1 vandetanib 1 telomerase reverse transcriptase p572Y, human 1 spartalizumab 1 sotorasib 1 olaparib 1 necitumumab 1 icotinib 1 durvalumab 1 dacomitinib 1 capivasertib 1 aumolertinib 1 Vinorelbine 1 Radiosurgery 1 Platinum 1 Paclitaxel 1 MLN 8237 1 LY3023414 1 Injections 1 GC Temporary Stopping 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02117167 2024-01-10

SAFIR02_Lung

UNICANCER

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡